Antithymocyte globulin (ATG) is increasingly used in preallogeneic stem cell transplantation (allo-SCT) conditioning regimens to prevent graft rejection and graft-versushost disease. However, ATG was also found to be associated with increased incidence of thrombosis during organ transplantation. In the present study, we tested the coagulation status of 21 patients with hematologic malignancies undergoing allo-SCT who received ATGbased (11 patients) or non-ATG-based (10) conditioning treatment. We assessed several thrombophilia markers as well as circulating total and endothelial microparticles (TMP/EMP) and soluble CD40 ligand (CD40L). No significant difference in the mean values of prothrombin time, partial thromboplastin time, fibrinogen, antithrombin, protein C, protein S, thrombin-antithrombin III complex, homocysteine levels, prevalence of genetic thrombophilia markers and levels of EMP, TMP or CD40L was observed between the ATG-treated and ATGuntreated patients, as well as before and after conditioning in each group separately. Platelet counts decreased significantly in ATG-treated patients; however, this decrease was not associated with clinical or laboratory evidence of disseminated intravascular coagulation. No patient developed thromboembolic event or veno-occlusive liver disease. Our results suggest that allo-SCT is not associated with increased hypercoagulability and addition of ATG to conditioning regimen has no significant procoagulant effect.
Summary:
Antithymocyte globulin (ATG) is increasingly used in preallogeneic stem cell transplantation (allo-SCT) conditioning regimens to prevent graft rejection and graft-versushost disease. However, ATG was also found to be associated with increased incidence of thrombosis during organ transplantation. In the present study, we tested the coagulation status of 21 patients with hematologic malignancies undergoing allo-SCT who received ATGbased (11 patients) or non-ATG-based (10) conditioning treatment. We assessed several thrombophilia markers as well as circulating total and endothelial microparticles (TMP/EMP) and soluble CD40 ligand (CD40L). No significant difference in the mean values of prothrombin time, partial thromboplastin time, fibrinogen, antithrombin, protein C, protein S, thrombin-antithrombin III complex, homocysteine levels, prevalence of genetic thrombophilia markers and levels of EMP, TMP or CD40L was observed between the ATG-treated and ATGuntreated patients, as well as before and after conditioning in each group separately. Platelet counts decreased significantly in ATG-treated patients; however, this decrease was not associated with clinical or laboratory evidence of disseminated intravascular coagulation. No patient developed thromboembolic event or veno-occlusive liver disease. Our results suggest that allo-SCT is not associated with increased hypercoagulability and addition of ATG to conditioning regimen has no significant procoagulant effect. An association between the hemostatic system and cancer has been well known for many years. Thromboembolic phenomenae are common in patients with cancer in part due to procoagulant activities of tumor cells as well as tumor-mediated activation of the coagulation.
1,2 The risk of thrombosis in cancer patients is increased even further during chemotherapy. 3, 4 The markers of thrombin generation were found in the plasma of patients with hematological malignancies undergoing chemotherapy or bone marrow transplantation. 5, 6 In addition, decrease in antithrombin (AT) or protein C was reported following autologous or allogeneic bone marrow transplantation creating a potentially hypercoagulable state, which may contribute to thrombotic complications of bone marrow transplantation. [7] [8] [9] [10] In spite of the presumed hypercoagulable state only few patients develop overt thromboembolic complications. 10 Antithymocyte globulin (ATG) is one of the modalities for the prevention of rejection and graft-versus-host disease prophylaxis in patients undergoing allogeneic stem cell transplantation (allo-SCT) for hematological malignancies. Single reports emphasized ATG in the pathogenesis of venous and arterial thromboembolic events following ATG treatment. [11] [12] [13] [14] Anderson and Wood 11 have reported intravascular thrombosis and platelet aggregation in animals following intravenous administration of ATG. Mee and Evans 12 have described local thrombosis in humans receiving ATG. Simmons et al 13 also reported thrombosis following the use of ATG. Kimball et al 14 reported on procoagulant and platelet aggregating activities in five out of 10 ATG preparations. Finally, the incidence of thromboembolic events was reported to be significantly higher in renal allograft recipients treated with ATG-containing regimen. 15 Recently, ATG treatment was found to induce laboratory evidence of chronic disseminated intravascular coagulation (DIC). 16 Thus, ATG immunosuppression may confer a risk for thromboembolic disease in the post transplant period. However, the previous reports have not evaluated the effect of recently established thrombophilia markers on the prothrombotic potential of ATG. In addition, the role of new markers of coagulation/activation such as circulating microparticles (CMP) or CD40 ligand (CD40L) in the context of ATG treatment has not been studied. Precise evaluation of the prothrombotic activity of ATG is of great significance, since if such an activity is established prophylactic anticoagulant therapy during ATG therapy might be warranted. CMP are produced from the cell membrane after apoptotic cell death. They are released following cell activation when there is remodeling of the membrane leading to externalization of phospholipids, such as phosphotidylserine. 17 Microparticles in turn lead to increased expression of adhesion molecules, thereby amplifying the procoagulant and/or inflammatory response on the endothelial cell surface. 18, 19 Microparticles have been associated with several prothrombotic conditions such as thrombotic thrombocytopenic purpura, 20 myocardial infarction, 21 sepsis, 22 heparin-induced thrombocytopenia 23, 24 and pre-eclampsia. 25 Upon activation platelets may release inflammatory mediators such as CD40L, a transmembrane protein structurally related to the cytokine tumor necrosis factora that was identified on T cells and platelets. 26 A soluble form of CD40L can bind CD40 receptor expressed on a variety of cells, such as endothelial cells, platelets, macrophages, B cells and vascular smooth muscle cells, resulting in inflammatory responses. 27 The goal of the present study was to evaluate the effects of ATG on coagulation and endothelial cell activation in patients undergoing allo-SCT by testing coagulation and thrombophilia markers, as well as circulating total and endothelial microparticles (TMP/EMP) and soluble CD40L.
Methods

Patients
In all, 21 patients underwent HLA-matched allogeneic transplantation for acute (AML -seven patients) or chronic myelogenous leukemia (CML -four patients), non-Hodgkin's lymphoma (three patients), multiple myeloma (three patients), acute lymphoblastic leukemia (ALLtwo patients), myelodysplastic syndrome (one patient) and Hodgkin's disease (one patient). A total of 11 patients were conditioned with fludarabine-based regiments, six with Bu/ Cy and four with TBI-based regiments (Table 1 ). In total, 10 patients received ATG (Fresenius, Germany) in the conditioning regimen, while 11 patients were conditioned without ATG. Patients were allocated to treatment with ATG if they received stem cells from an unrelated donor (10 patients). Other than that, the conditioning regimens of the patients who received either related or unrelated donor stem cells were the same. Blood samples were obtained at day -10 before transplantation and following completion of the conditioning regimen, prior to infusion of donor cells (day 0). All patients received G-SCF-mobilized peripheral blood stem cell grafts.
Patients with previous history of thromboembolic events or pregnancy were excluded from the study.
The study was approved by the Human Investigation Review Board of the Chaim Sheba Medical Center. Each patient signed an informed consent form.
Coagulation tests
Nine parts of blood were drawn into one part of 3.8% sodium citrate. Citrated blood was centrifuged within 30 min at 2000 g (20 min) and plasma aliquots were stored at À351C. Prothrombin time (PT) and partial thromboplastin time (PTT) were measured by one-stage coagulation assays.
Protein C and AT activities were measured by chromogenic assays (Baxter Dade, Bonnstrasse, Switzerland), and free protein S antigen was measured by ELISA (Gradipore ELISA test kit, Riverside Corporate Park, Australia). Thrombin-antithrombin III complex (TAT) was measured with ELISA kit (Dade, Behring, Marburg, Germany).
Total plasma homocysteine was measured by the HPLCbased method of Jacobson et al. CMPs were measured by flow cytometry using fluorescent anti-CD51/CD31 antibodies for the detection of EMP and annexin V-PE for TMPs. Plasma levels of CD40L were measured using ELISA kit (Bender MedSystem Diagnostics Gmbh, Austria).
DNA analysis
For factor V Leiden (FVL), factor II mutation (FII G20210A) and MTHFR mutation 677TT, DNA was extracted from EDTA-anticoagulant blood samples using standard methods. FVL was detected by PCR amplification of a 267 bp fragment and MnII digestion, as described previously. 29 The C677T substitution in the MTHFR gene was identified using Hinfl cleavage of a 198 bp PCRamplified product as described by Frosst et al. 30 For identification of the G20210A substitution in the factor II gene, a slight modification of the method of Poort and co-workers was used. 29 
Statistical analysis
All analyses were carried out utilizing SPSS (ver. 10, Chicago, IL, USA). Patient characteristics, data on the levels of AT and proteins C and S and levels of TMPs and EMPs were compared between groups (ATG þ and ATGÀ) with unpaired t-test or the equivalent nonparametric tests, whereas comparison before (day À10) and after (day 0) allo-SCT was made with the paired t-test. Proportions were analyzed with the use of Fisher's exact tests. Data are presented as mean7s.d. or as median and interquartile range (IQR, percentile 25-75% range). All P-values are two-sided. A P-value o0.05 was considered significant.
Results
Among the 21 patients who underwent allo-SCT, 10 received ATG. Clinical characteristics of the two groups are presented in Table 1 . Both groups of patients were similar at baseline with regard to gender, stem cell source and underlying disease, although, ATG-treated patients were younger than patients who did not receive ATG (P ¼ 0.002). Liver function tests were similar between the groups; however, two ATG-treated and one ATG-untreated patient had minor elevations (p3 times above the normal range) of transaminases following conditioning treatment (data not shown), but during follow-up liver function tests normalized spontaneously in all patients.
None of the ATG-treated or ATG-untreated patients developed thromboembolic event or veno-occlusive disease of the liver (VOD).
No difference in the prevalence of the genetic polymorphisms was observed between the groups: three patient in the ATG-treated group and two patients in the ATGuntreated group were homozygous for the MTHFR C677T mutation and one patient in the ATG-untreated group was heterozygous for the FVL mutation. None of the patients was heterozygous for FII mutation.
The values of all the coagulation parameters measured in each individual patient are shown in Table 2 . No significant difference in the mean values of PT, PTT, fibrinogen, AT, protein C, protein S and homocysteine blood levels was observed between the ATG-treated and ATG-untreated patients, as well as between days À10 and 0 in each group separately. Similarly, no differences were found for all the above-mentioned parameters in patients conditioned with fludarabine-based reduced intensity conditioning compared to standard myeloablative conditioning regimen, or between patients who received unrelated vs related donor stem cell transplantation.
In both ATG-treated and ATG-untreated patients, a slight increase in TAT was observed following the treatment (Table 2) . However, the difference between the groups as well as within each group before and after ATG treatment has not reached statistical significance. Platelet counts decreased following the conditioning treatment in both ATG-treated and ATG-untreated groups; however, counts decreased in a statistically significant manner (P ¼ 0.028) only in the ATG-treated group ( Table 2) .
The distribution of TMP and EMP in each group of patients is shown in Figure 1 . In ATG-treated patients, the median levels of TMP and EMP before and after conditioning were not significantly different: 39 750 mp/ml (IQR: 58 200 mp/ml) vs 29 700 mp/ml (IQR: 135 650 mp/ ml), P ¼ 0.92 for TMP and 24 000 mp/ml (IQR: 64 750 mp/ ml) vs 12 050 mp/ml (IQR: 78 300 mp/ml), P ¼ 0.17 for EMP. Similarly, in patients not treated with ATG, the median (IQR) levels of TMP or EMP before and after conditioning were not significantly different: 45 700 mp/ml (IQR: 57 000 mp/ml) vs 33 000 (IQR: 36 500 mp/ml), respectively, P ¼ 0.48 for TMP and 28 600 (IQR: 49 000 mp/ ml) vs 22 900 (IQR: 32 000 mp/ml), respectively, P ¼ 0.97 for EMP (Figure 1) . The median TMP levels obtained in 15 healthy controls were 67 000 mp/ml (IQR: 36 000 mp/ml) and median EMP levels were 24 000 mp/ml (IQR: 16 000 mp/ml).
The distribution of CD40L in both groups before and after conditioning is shown in Figure 2 . No statistically significant difference in the median CD40L before and after the conditioning in ATG-untreated or ATG-treated groups was observed: 0.15 ng/ml (IQR: 0.60 ng/ml) vs 0.00 ng/ml (IQR: 0.15 ng/ml), P ¼ 0.64 and 0.15 ng/ml (IQR: 0.45 ng/ ml) vs 0.15 ng/ml (IQR: 0.19 ng/ml), P ¼ 0.79, respectively. The median CD40L values obtained in 11 normal controls were: 0.15 ng/ml (IQR: 0.30 ng/ml). Similarly, no difference in each of these values was observed between ATG-treated and ATG-untreated groups.
Discussion
This study is a prospective study, where the effect of ATG on the hemostatic system of patients undergoing allo-SCT was evaluated. The baseline characteristics of the ATGtreated and ATG-untreated patients were similar including the prevalence of genetic thrombophilia polymorphisms. Our results show that no difference in the values of AT III, protein C, protein S and homocysteine before and after the transplantation was observed in either ATG-treated or ATG-untreated groups. This indicates that conditioning therapy including ATG has no effect on either levels of physiological inhibitors of coagulation or homocysteine.
Although a slight increase in TAT complexes measured in each ATG-treated or ATG-untreated groups before and after conditioning was observed, the difference was not statistically significant. These results are in contrast to those reported by Weber et al, 16 who found an increase in D-Dimer and TAT complexes following ATG treatment, suggesting that ATG treatment induces a state of nonovert DIC. The difference between our results and those reported by Weber et al may stem in part from the fact that one-third of their patients treated with ATG received HLA-mismatched grafts. In HLA-mismatched grafts an antibody-mediated vascular injury of the allograft may generate Schwartzman's phenomena known to be associated with DIC. 31 This is further supported by the lack of significant TAT increase observed in their ATG-untreated patients who received only HLA-matched grafts.
Similarly to Weber et al, 16 we observed a decrease in platelet count after the conditioning in all the patients; however, the decrease was statistically significant only in the group treated with ATG (P ¼ 0.028). Since no difference in PT, PTT, fibrinogen, AT and TAT levels was observed between ATG-treated and ATG-untreated patients, we believe that chemotherapy induced bone marrow suppression and not DIC, is the most likely explanation for the decrease in platelets. In addition, thrombocytopenia is a well-known toxicity of ATG.
Since CMP and CD40L are novel markers of procoagulability and cell activation, an increase in these markers in the plasma may reflect the endothelial cell activation, injury or procoagulant state that may be associated with highdose chemotherapy. However, no significant difference in the levels of TMP or EMP was observed in our study in ATG-treated patients before and after the conditioning. Similarly, in patients not treated with ATG the levels of TMP or EMP before and after conditioning were not significantly different. In addition, no statistically significant difference in the distribution of CD40L in each ATG-treated or ATG-untreated groups before and after conditioning was observed. However, it should be noted that these results might be affected by the small sample size.
In summary, our findings suggest that HLA-matched allogeneic transplantation with or without ATG pretreatment has no visible procoagulant effect on the coagulation status of the patients.
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